Cargando…

A Joint Model for the Kinetics of CTC Count and PSA Concentration During Treatment in Metastatic Castration-Resistant Prostate Cancer*

Assessment of treatment efficacy in metastatic castration-resistant prostate cancer (mCRPC) is limited by frequent nonmeasurable bone metastases. The count of circulating tumor cells (CTCs) is a promising surrogate marker that may replace the widely used prostate-specific antigen (PSA). The purpose...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wilbaux, M, Tod, M, De Bono, J, Lorente, D, Mateo, J, Freyer, G, You, B, Hénin, E
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BlackWell Publishing Ltd 2015
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4452933/ https://www.ncbi.nlm.nih.gov/pubmed/26225253 http://dx.doi.org/10.1002/psp4.34

Ejemplares similares

Prediction of tumour response induced by chemotherapy using modelling of CA-125 kinetics in recurrent ovarian cancer patients
por: Wilbaux, M, et al.
Publicado: (2014)

Early prediction of treatment resistance in low-risk gestational trophoblastic neoplasia using population kinetic modelling of hCG measurements
por: You, B, et al.
Publicado: (2013)

Low hemoglobin and PSA kinetics are prognostic factors of overall survival in metastatic castration-resistant prostate cancer patients
por: Hakozaki, Yuji, et al.
Publicado: (2023)

Radiographic progression with nonrising PSA in metastatic castration-resistant prostate cancer: post hoc analysis of PREVAIL
por: Bryce, A H, et al.
Publicado: (2017)

PSA Kinetics as Prognostic Markers of Overall Survival in Patients with Metastatic Castration-Resistant Prostate Cancer Treated with Abiraterone Acetate
por: España, Sofia, et al.
Publicado: (2020)

Modeled Early Longitudinal PSA Kinetics Prognostic Value in Rising PSA Prostate Cancer Patients after Local Therapy Treated with ADT +/− Docetaxel
por: Carrot, Aurore, et al.
Publicado: (2022)

Improving power in PSA response analyses of metastatic castration-resistant prostate cancer trials
por: Grayling, Michael J., et al.
Publicado: (2022)

Multiple Docetaxel Retreatments Without Prednisone for Metastatic Castration-Resistant Prostate Cancer in the Docetaxel-Only Era: Effects on PSA Kinetics and Survival
por: Maj-Hes, Agnieszka, et al.
Publicado: (2021)

Baseline Plasma Tumor DNA (ctDNA) Correlates with PSA Kinetics in Metastatic Castration-Resistant Prostate Cancer (mCRPC) Treated with Abiraterone or Enzalutamide
por: Conteduca, Vincenza, et al.
Publicado: (2022)

Prolonged PSA stabilization and overall survival following sipuleucel-T monotherapy in metastatic castration-resistant prostate cancer patients
por: Holl, Eda K., et al.
Publicado: (2019)

Aneuploid CTC and CEC
por: Lin, Peter Ping
Publicado: (2018)

Association of early PSA decline and time to PSA progression in abiraterone acetate-treated metastatic castration-resistant prostate cancer; a post-hoc analysis of Japanese phase 2 trials
por: Nakayama, Masahiko, et al.
Publicado: (2016)

OSM potentiates preintravasation events, increases CTC counts, and promotes breast cancer metastasis to the lung
por: Tawara, Ken, et al.
Publicado: (2018)

Baseline CTC Count as a Predictor of Long-Term Outcomes in High-Risk Prostate Cancer
por: Cieślikowski, Wojciech A., et al.
Publicado: (2023)

PSA kinetics before 40 years of age
por: Pazeto, Cristiano Linck, et al.
Publicado: (2018)

PSA declines and survival in patients with metastatic castration-resistant prostate cancer treated with enzalutamide: A retrospective case-report study
por: Bosso, Davide, et al.
Publicado: (2017)

Prevalence and Prognostic Implications of PSA Flares during Radium-223 Treatment among Men with Metastatic Castration Resistant Prostate Cancer
por: Sidhu, Amanjot, et al.
Publicado: (2023)

miRNA in situ hybridization in circulating tumor cells - MishCTC
por: Ortega, Francisco G., et al.
Publicado: (2015)

HER2-targeted therapy influences CTC status in metastatic breast cancer
por: Deutsch, Thomas M., et al.
Publicado: (2020)

RNA-Based CTC Analysis Provides Prognostic Information in Metastatic Breast Cancer
por: Strati, Areti, et al.
Publicado: (2021)

Magnetic Particles for CTC Enrichment
por: Liu, Peng, et al.
Publicado: (2020)

Pain, PSA flare, and bone scan response in a patient with metastatic castration-resistant prostate cancer treated with radium-223, a case report
por: McNamara, Megan A, et al.
Publicado: (2015)

Recent Update Roles of Magnetic Nanoparticles in Circulating Tumor Cell (CTC)/Non-CTC Separation
por: Pipatwatcharadate, Chawapon, et al.
Publicado: (2023)

Assessment of a prognostic model, PSA metrics and toxicities in metastatic castrate resistant prostate cancer using data from Project Data Sphere (PDS)
por: Pitcher, Bethany, et al.
Publicado: (2017)

Lenalidomide decreased the PSA level for castration‐resistant prostate cancer: a case report
por: Shimokihara, Kota, et al.
Publicado: (2018)

Dynamic changes of alkaline phosphatase are strongly associated with PSA-decline and predict best clinical benefit earlier than PSA-changes under therapy with abiraterone acetate in bone metastatic castration resistant prostate cancer
por: Mikah, Phillip, et al.
Publicado: (2016)

Premio literario CTC : Concurso Rubén Martínez Villena.
Publicado: (1976)

Nadir PSA level and time to nadir PSA are prognostic factors in patients with metastatic prostate cancer
por: Tomioka, Atsushi, et al.
Publicado: (2014)

Relationship between initial PSA density with future PSA kinetics and repeat biopsies in men with prostate cancer on active surveillance
por: Kotb, A F, et al.
Publicado: (2011)

Sequential Isolation and Characterization of Single CTCs and Large CTC Clusters in Metastatic Colorectal Cancer Patients
por: Francescangeli, Federica, et al.
Publicado: (2021)

Metastatic prostate cancer in the modern era of PSA screening
por: Fontenot, Philip A., et al.
Publicado: (2017)

Exponential Rise in Prostate-Specific Antigen (PSA) during Anti-Androgen Withdrawal Predicts PSA Flare after Docetaxel Chemotherapy in Patients with Castration-Resistant Prostate Cancer
por: Han, Kyung Seok, et al.
Publicado: (2015)

Clinical Variables Associated with PSA Response to Lutetium-177-PSMA ([177Lu]-PSMA-617) Radionuclide Treatment in Men with Metastatic Castration-Resistant Prostate Cancer
por: Gadot, Moran, et al.
Publicado: (2020)

Effect of Kidney Function on Drug Kinetics and Dosing in Neonates, Infants, and Children
por: Rodieux, Frederique, et al.
Publicado: (2015)

Sensitivity of (18)F-fluorodihydrotestosterone PET-CT to count statistics and reconstruction protocol in metastatic castration-resistant prostate cancer
por: Cysouw, Matthijs C. F., et al.
Publicado: (2019)

Tumour responses following a steroid switch from prednisone to dexamethasone in castration-resistant prostate cancer patients progressing on abiraterone
por: Lorente, D, et al.
Publicado: (2014)

CtcS, a MarR family regulator, regulates chlortetracycline biosynthesis
por: Kong, Lingxin, et al.
Publicado: (2019)

DanioCTC: Analysis of Circulating Tumor Cells from Metastatic Breast Cancer Patients in Zebrafish Xenografts
por: Reinhardt, Florian, et al.
Publicado: (2023)

PSA and PSA Kinetics Thresholds for the Presence of (68)Ga-PSMA-11 PET/CT-Detectable Lesions in Patients with Biochemical Recurrent Prostate Cancer
por: Hoffmann, Manuela Andrea, et al.
Publicado: (2020)

Technical Challenges for CTC Implementation in Breast Cancer
por: Ramos-Medina, Rocío, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_itaqfp9rkrl2e9rfih4pghshr8